In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.

Thulien, Kyle J; Belch, Andrew R; Reiman, Tony; Pilarski, Linda M

Thulien, Kyle J; Belch, Andrew R; Reiman, Tony; Pilarski, Linda M.

Affiliation

Thulien KJ; Department of Oncology, University of Alberta and Cross Cancer Institute, 11560 University Avenue, Edmonton, AB, T6G1Z2, Canada.

Mol Cancer ; 11: 78, 2012 Oct 19.

Article in En | MEDLINE | ID: mdl-23083101

Subject(s)

Immunoglobulin Heavy Chains/genetics; Multiple Myeloma/genetics; Multiple Myeloma/mortality; V(D)J Recombination; Aged; Aged, 80 and over; Clone Cells; Humans; Induction Chemotherapy; Multiple Myeloma/drug therapy; Prognosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunoglobulin Heavy Chains / V(D)J Recombination / Multiple Myeloma Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans Language: En Journal: Mol Cancer Journal subject: NEOPLASIAS Year: 2012 Type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google